| |
|
|
|
|
|
|
|||
|
Blood, 23 July 2009, Vol. 114, No. 4, pp. 779-784. Prepublished online as a Blood First Edition Paper on April 8, 2009; DOI 10.1182/blood-2009-01-195313.
CLINICAL TRIALS AND OBSERVATIONS Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders1 Transfusion Service, Hemophilia and Regional Blood Disease Centre, Castelfranco Veneto, Castelfranco Veneto; 2 Vascular and Internal Medicine, University of Perugia, Perugia; 3 Angelo Bianchi Bonomi Hemophilia and Thrombosis Centre, Department of Medicine and Medical Specialties, University of Milan and Istituto Di Ricovero e Cura a Carattere Scientifico (IRCCS) Maggiore Hospital, Mangiagalli and Regina Elena Foundation, Milan; 4 Agency for Hemophilia, Azienda Ospedaliera Universitaria Careggi, Florence; 5 Department of Orthopedics, Castelfranco Veneto, Castelfranco Veneto; 6 Clinica Ortopedica II, Azienda Ospedaliera Universitaria Careggi, Florence; 7 Department of Cellular Biotechnology and Haematology, University La Sapienza, Rome; 8 Traumatology Unit, IRCCS Maggiore Hospital, Mangiagalli and Regina Elena Foundation, Milan; 9 Unità Operativa di Angiologia e Malattie della Coagulazione "Marino Golinelli" Azienda Ospedaliera di Bologna Policlinico S Orsola, Bologna; and 10 Internal Medicine, Hemophilia Centre, Bari, Italy Data from the Italian Hemophilia Centres were collected to perform a retrospective survey of joint arthroplasty in patients with severe hemophilia. Twenty-nine of 49 hemophilia centers reported that 328 of the 347 operations were carried out in 253 patients with severe hemophilia A (HA) and 19 in 15 patients with severe hemophilia B (HB). When results were normalized to the whole Italian hemophilia population (1770 severe HA and 319 severe HB), patients with HA had a 3-fold higher risk of undergoing joint arthroplasty (odds ratio [OR], 3.38; 95% confidence interval [CI], 1.97-5.77; P < .001). These results were confirmed after adjustment for age, HIV, hepatitis C virus (HCV), and inhibitor in a Cox regression model (HR, 2.65; 95% CI, 1.62-4.33; P < .001). The survival analysis of time to joint arthroplasty in the subset of patients with severe HA was not affected by the severity of factor VIII (FVIII) gene mutations. A systematic review of literature articles reporting joint arthroplasties in HA and HB showed that the proportion of HA patients who had undergone arthroplasties was higher than that of HB patients, in agreement with the findings in our Italian cohort. These data suggest that the 2 inherited coagulation disorders have a different severity of clinical phenotype.
Related Articles in Blood Online:
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2009 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||